News NICE guidance calls for quicker diagnosis of PMOS Women with polyendocrine metabolic ovarian syndrome (PMOS) should be diagnosed sooner and be offered an annual review, according to new NICE guidance.
News Roivant wins FDA approval for first targeted dermatomyositis... Roviant & Priovant Therapeutics finally secure US approval for once-daily oral TYK2/JAK1 inhibitor, Lisraya (brepocitinib), for dermatomyositis.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.